Axogen (AXGN) Cash from Financing Activities (2010 - 2026)
Axogen (AXGN) posted quarterly Cash from Financing Activities of $4.2 million for Q2 2026, up 262.75% year-over-year from $1.2 million in Q2 2025, and down 92.95% quarter-over-quarter from $59.5 million in Q1 2026.
Axogen (AXGN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Axogen's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $4.2 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 262.75% year-over-year to $4.2 million; the TTM figure through Jun 2026 stood at $70.7 million (up 1290.71% YoY), while the FY2025 annual figure was $10.5 million, up 358.47% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at $4.2 million, down from $59.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $59.5 million in Q1 2026, with the low at $5000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $742000.0 (2022), against an average of $4.5 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 97.67% in 2023, then jumped 11340.0% in 2024.
- Axogen's Cash from Financing Activities stood at $813000.0 in 2022, then plunged by 48.59% to $418000.0 in 2023, then surged by 132.06% to $970000.0 in 2024, then soared by 370.72% to $4.6 million in 2025, then fell by 8.08% to $4.2 million in 2026.
- Business Quant data shows AXGN's Cash from Financing Activities at $4.2 million in Q2 2026, $59.5 million in Q1 2026, and $4.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Axogen | 2.49 Bn | 2.38 Bn | 50.67 Mn | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | 59.51 Mn |
| Mar 31, 2026 | 59.51 Mn |
| Dec 31, 2025 | 4.57 Mn |
| Dec 31, 2025 | 4.57 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 970,000.00 |
| Dec 31, 2024 | 970,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 544,000.00 |
| Jun 30, 2024 | 544,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Mar 31, 2024 | 204,000.00 |